Marybeth K Farazdaghi1,2, William R Katowitz1,2, Robert A Avery1,2,3. 1. Division of Ophthalmology, The Children's Hospital of Philadelphia. 2. Department of Ophthalmology. 3. Department of Neurology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Optic pathway gliomas are low-grade neoplasms that affect the precortical visual pathway of children and adolescents. They can affect the optic nerve, optic chiasm, optic tracts and radiations and can either be sporadic or associated with neurofibromatosis type one. Gliomas isolated to the optic nerve (ONG) represent a subgroup of optic pathway gliomas, and their treatment remains controversial. New developments in ONG treatment have emerged in recent years, and it is necessary for clinicians to have a current understanding of available therapies. RECENT FINDINGS: The current review of the literature covers the background of and recent developments in ONG treatment, with a focus on standard chemotherapy, new molecularly targeted therapies, radiation therapy and surgical resection and debulking. SUMMARY: Although standard chemotherapy remains the mainstay of ONG treatment, newer molecularly targeted therapies such as mitogen-activated protein kinase kinase inhibitors and bevacizumab represent a promising new treatment modality, and clinical studies are ongoing.
PURPOSE OF REVIEW: Optic pathway gliomas are low-grade neoplasms that affect the precortical visual pathway of children and adolescents. They can affect the optic nerve, optic chiasm, optic tracts and radiations and can either be sporadic or associated with neurofibromatosis type one. Gliomas isolated to the optic nerve (ONG) represent a subgroup of optic pathway gliomas, and their treatment remains controversial. New developments in ONG treatment have emerged in recent years, and it is necessary for clinicians to have a current understanding of available therapies. RECENT FINDINGS: The current review of the literature covers the background of and recent developments in ONG treatment, with a focus on standard chemotherapy, new molecularly targeted therapies, radiation therapy and surgical resection and debulking. SUMMARY: Although standard chemotherapy remains the mainstay of ONG treatment, newer molecularly targeted therapies such as mitogen-activated protein kinase kinase inhibitors and bevacizumab represent a promising new treatment modality, and clinical studies are ongoing.
Authors: Laura-Nanna Lohkamp; Patricia Parkin; Allan Puran; Ute Katharina Bartels; Eric Bouffet; Uri Tabori; James Thomas Rutka Journal: Front Surg Date: 2022-05-03
Authors: Lily Deland; Simon Keane; Thomas Olsson Bontell; Helene Sjögren; Henrik Fagman; Ingrid Øra; Esther De La Cuesta; Magnus Tisell; Jonas A Nilsson; Katarina Ejeskär; Magnus Sabel; Frida Abel Journal: Cancer Biol Ther Date: 2021-04-05 Impact factor: 4.742
Authors: Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel Journal: Curr Oncol Rep Date: 2021-03-15 Impact factor: 5.075
Authors: Christopher S Hong; Greg Fliney; Adeniyi Fisayo; Yi An; Pallavi P Gopal; Antonio Omuro; Renelle Pointdujour-Lim; E Zeynep Erson-Omay; S Bulent Omay Journal: Brain Tumor Pathol Date: 2020-10-24 Impact factor: 3.298